Patient presents with complaints consistent with advanced prostate cancer.  Symptoms include persistent bone pain, fatigue, and weight loss.  Digital rectal exam revealed an enlarged, hard, and nodular prostate.  Elevated prostate-specific antigen (PSA) levels were noted, significantly exceeding the normal range.  Biopsy results confirm the diagnosis of prostate adenocarcinoma, Gleason score [insert Gleason score], with evidence of metastasis.  Imaging studies, including bone scan and CT scan of the abdomen and pelvis, demonstrate metastatic lesions in [specify location of metastases, e.g., bone, lymph nodes, liver].  The patient's medical history includes [list relevant medical history, e.g., hypertension, diabetes].  Current medications include [list current medications].  The patient was counseled regarding treatment options for metastatic prostate cancer, including androgen deprivation therapy (ADT), chemotherapy, radiation therapy, and potential clinical trials.  Risks and benefits of each treatment modality were discussed.  The patient's performance status was assessed using the Eastern Cooperative Oncology Group (ECOG) scale and determined to be [ECOG score].  A treatment plan was developed in conjunction with the patient's preferences and overall health status.  Follow-up appointments were scheduled for monitoring of treatment response and management of potential side effects.  Diagnosis codes include C61 (malignant neoplasm of prostate) and C79.51 (secondary malignant neoplasm of bone and bone marrow).  Relevant billing codes may include [insert relevant CPT codes for procedures performed, e.g., biopsy, imaging studies, consultations].  Prognosis discussed with patient and family.  Palliative care options were also addressed.